{"id":"cggv:1ae8da5f-7a0b-45f5-b60e-20af39cc41c1v1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:1ae8da5f-7a0b-45f5-b60e-20af39cc41c1_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10135","date":"2023-08-02T16:00:00.000Z","role":"Approver"},{"id":"cggv:1ae8da5f-7a0b-45f5-b60e-20af39cc41c1_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10135","date":"2024-05-16T17:48:05.228Z","role":"Publisher"}],"curationReasons":{"id":"cg:NewCuration"},"earliestArticle":{"id":"https://pubmed.ncbi.nlm.nih.gov/19625727","type":"dc:BibliographicResource","dc:creator":"Stojkovic T","dc:date":"2009","dc:title":"Muscle glycogenosis due to phosphoglucomutase 1 deficiency."},"evidence":[{"id":"cggv:1ae8da5f-7a0b-45f5-b60e-20af39cc41c1_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:1ae8da5f-7a0b-45f5-b60e-20af39cc41c1_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:3ed3185e-1a69-458a-8da4-7df69c306944","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:7ba04e3d-41e0-4fb8-bcc4-ff6c91360e90","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionB"},"dc:description":"Patient fibroblasts showed increased concentrations of Gal-1-P and Glu-1-P; ratio of UDP-gal and UDP-glu was decreased, suggesting defective N-glycan biosynthesis. Addition of galactose to culture medium of patient fibroblasts and as dietary supplement to patients enhanced glycosylation of ICAM-1 and transferrin, respectively, suggesting rescue of PGm1 defect.\n","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24499211","type":"dc:BibliographicResource","dc:abstract":"Congenital disorders of glycosylation are genetic syndromes that result in impaired glycoprotein production. We evaluated patients who had a novel recessive disorder of glycosylation, with a range of clinical manifestations that included hepatopathy, bifid uvula, malignant hyperthermia, hypogonadotropic hypogonadism, growth retardation, hypoglycemia, myopathy, dilated cardiomyopathy, and cardiac arrest.","dc:creator":"Tegtmeyer LC","dc:date":"2014","dc:title":"Multiple phenotypes in phosphoglucomutase 1 deficiency."},"rdfs:label":"Tegtmeyer_PGM1 function"}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":2,"dc:description":"The function of PGM1 is well understood and deficiency in the activity of this enzyme is directly involved in the disease mechanism, warranting maximum points."}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"cggv:1ae8da5f-7a0b-45f5-b60e-20af39cc41c1_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:027b7af8-96c2-4183-8dbe-de82a2c99491","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:27d0750a-338c-48a2-8b80-bb075615e071","type":"Finding","demonstrates":{"id":"cg:PhenotypeRescue"},"dc:description":"Echocardiography showed progressive deterioration of cardiac function in the cohort without treatment. In cKO mice treated with AAv9-Pgm2 prior to tamoxifen feeding, treatment completely prevented the development of DCM. Mice treated after the development of cardiac features, did not develop further worsening of the cardiac functions and exhibited no excess accumulation of glycogen or fibrosis.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/36709920","type":"dc:BibliographicResource","dc:abstract":"Phosphoglucomutase 1 (PGM1) deficiency is recognized as the third most common N-linked congenital disorders of glycosylation (CDG) in humans. Affected individuals present with liver, musculoskeletal, endocrine, and coagulation symptoms; however, the most life-threatening complication is the early onset of dilated cardiomyopathy (DCM). Recently, we discovered that oral D-galactose supplementation improved liver disease, endocrine, and coagulation abnormalities, but does not alleviate the fatal cardiomyopathy and the associated myopathy. Here we report on left ventricular ejection fraction (LVEF) in 6 individuals with PGM1-CDG. LVEF was pathologically low in most of these individuals and varied between 10% and 65%. To study the pathobiology of the cardiac disease observed in PGM1-CDG, we constructed a novel cardiomyocyte-specific conditional Pgm2 gene (mouse ortholog of human PGM1) knockout (Pgm2 cKO) mouse model. Echocardiography studies corroborated a DCM phenotype with significantly reduced ejection fraction and left ventricular dilation similar to those seen in individuals with PGM1-CDG. Histological studies demonstrated excess glycogen accumulation and fibrosis, while ultrastructural analysis revealed Z-disk disarray and swollen/fragmented mitochondria, which was similar to the ultrastructural pathology in the cardiac explant of an individual with PGM1-CDG. In addition, we found decreased mitochondrial function in the heart of KO mice. Transcriptomic analysis of hearts from mutant mice demonstrated a gene signature of DCM. Although proteomics revealed only mild changes in global protein expression in left ventricular tissue of mutant mice, a glycoproteomic analysis unveiled broad glycosylation changes with significant alterations in sarcolemmal proteins including different subunits of laminin-211, which was confirmed by immunoblot analyses. Finally, augmentation of PGM1 in KO mice via AAV9-PGM1 gene replacement therapy prevented and halted the progression of the DCM phenotype.","dc:creator":"Balakrishnan B","dc:date":"2023","dc:title":"AAV-based gene therapy prevents and halts the progression of dilated cardiomyopathy in a mouse model of phosphoglucomutase 1 deficiency (PGM1-CDG)."},"rdfs:label":"Balakrishnan_cKO rescue"}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":2,"dc:description":"Default points are awarded for the rescue of the cardiac phenotype in the DCM mouse model of PGM1."},{"id":"cggv:6f601cb2-dc3c-429a-807f-994cd577e5d5","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:775a7752-87a9-41e6-aae5-85b0c25b86c8","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Constitutive knock-out of Pgm2 (KO) leads to embryonic lethality, which included all homozygotes and several heterozygotes. Embryonic development was noted to be arrested at around E9.5. Galactose supplementation did not rescue lethality. Heterozygous Pgm2+/- mice showed significant reduction (>60%) in Pgm2 activity and a distinct glycosylation pattern compared to that of WT and human PGM1 deficient patients.\n","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/31077402","type":"dc:BibliographicResource","dc:abstract":"Patients with phosphoglucomutase (PGM1) deficiency, a congenital disorder of glycosylation (CDG) suffer from multiple disease phenotypes. Midline cleft defects are present at birth. Overtime, additional clinical phenotypes, which include severe hypoglycemia, hepatopathy, growth retardation, hormonal deficiencies, hemostatic anomalies, frequently lethal, early-onset of dilated cardiomyopathy and myopathy emerge, reflecting the central roles of the enzyme in (glycogen) metabolism and glycosylation. To delineate the pathophysiology of the tissue-specific disease phenotypes, we constructed a constitutive Pgm2 (mouse ortholog of human PGM1)-knockout (KO) mouse model using CRISPR-Cas9 technology. After multiple crosses between heterozygous parents, we were unable to identify homozygous life births in 78 newborn pups (P = 1.59897E-06), suggesting an embryonic lethality phenotype in the homozygotes. Ultrasound studies of the course of pregnancy confirmed Pgm2-deficient pups succumb before E9.5. Oral galactose supplementation (9 mg/mL drinking water) did not rescue the lethality. Biochemical studies of tissues and skin fibroblasts harvested from heterozygous animals confirmed reduced Pgm2 enzyme activity and abundance, but no change in glycogen content. However, glycomics analyses in serum revealed an abnormal glycosylation pattern in the Pgm2","dc:creator":"Balakrishnan B","dc:date":"2019","dc:title":"A novel phosphoglucomutase-deficient mouse model reveals aberrant glycosylation and early embryonic lethality."},"rdfs:label":"Balakrishnan_KO Mouse"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1,"dc:description":"Reduced score is awarded as mouse model does not recapitulate human phenotype, but in contrast shows that mouse Pgm2 is essential for development and is intolerant to loss of function, adding support to the role of PGM1 in human disease."},{"id":"cggv:bfbe716c-7f0d-422f-a24f-90901af14ccb","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:975b5902-2375-44ab-a1f1-e78e3533a451","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"cKO mice develop DCM - significantly dilated left ventricles visible at 4w after tamoxifen feeding, along with decreased fractional shortening (FS), ejection fraction (EF), and increased left ventricular end-diastolic internal dimensions (LVID-d) whereas WT mice displayed normal cardiac size. Fibrosis and glycogen accumulation were noted in cKO mouse hearts. TEM revealed disrupted myofibrillar organization, reduced mitochondrial matrix density, and fragmented mitochondrial cristae in Pgm2 cKO mice, similar to a heart examined from a PGM1-CDG patient","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36709920","rdfs:label":"Balakrishnan_conditional KO mouse"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2,"dc:description":"The cardiomyocyte-specific conditional knock-out mouse recapitulates the dilated cardiomyopathy phenotype observed in human patients with PGM1 deficiency."}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6},{"id":"cggv:1ae8da5f-7a0b-45f5-b60e-20af39cc41c1_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:b7329b25-840f-4ef4-b60d-ae594eb7864c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:b7329b25-840f-4ef4-b60d-ae594eb7864c","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":33,"allele":[{"id":"cggv:c5bac8eb-c4f0-40e9-a08f-25099e0d4dae","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002633.3(PGM1):c.787G>T (p.Asp263Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA156393"}},{"id":"cggv:dea73930-934e-4684-80db-f61b8261ffe4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002633.3(PGM1):c.788A>G (p.Asp263Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340649844"}}],"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Proband's lowest blood glucose was 1.9 mM, height <3pc","phenotypes":["obo:HP_0004322","obo:HP_0031964","obo:HP_0031956","obo:HP_0000193","obo:HP_0001695"],"previousTesting":true,"previousTestingDescription":"PGM1 activity was 2.4% of WT","sex":"Male","variant":[{"id":"cggv:d2e29603-e121-465b-971b-1fa1ab92b93e_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:dea73930-934e-4684-80db-f61b8261ffe4"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24499211"},{"id":"cggv:8e083b24-ae65-497e-83ae-19518083d78a_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c5bac8eb-c4f0-40e9-a08f-25099e0d4dae"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24499211"}],"rdfs:label":"Tegtmeyer_Proband 3"},{"id":"cggv:8e083b24-ae65-497e-83ae-19518083d78a","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:8e083b24-ae65-497e-83ae-19518083d78a_variant_evidence_item"},{"id":"cggv:8e083b24-ae65-497e-83ae-19518083d78a_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Lee et al, 2014; PMID: 25288802 showed that when variant was expressed in E. coli cells the resulting PGM1 soluble protein was expressed at levels similar to WT; however, the Kcat was 1.1% of WT."}],"strengthScore":0.5,"dc:description":"The proband was compound heterozygous for two missense variants supported by functional evidence and confirmed in trans. The Asp263Tyr variant is reported in gnomAD v2.1.1 at a frequency of 0.00007349 (5/68032 NFE alleles), with 0 homozygotes."},{"id":"cggv:d2e29603-e121-465b-971b-1fa1ab92b93e","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:d2e29603-e121-465b-971b-1fa1ab92b93e_variant_evidence_item"},{"id":"cggv:d2e29603-e121-465b-971b-1fa1ab92b93e_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Lee et al, 2014; PMID: 25288802 showed that when variant was expressed in E. coli cells the resulting PGM1 soluble protein was expressed at levels similar to WT; however, the Kcat was 2.1% of WT."}],"strengthScore":0.5,"dc:description":"The proband was compound heterozygous for two missense variants supported by functional evidence and confirmed in trans. The Asp263Gly variant is reported in gnomAD v2.1.1 at a frequency of 0.00005428 (7/128968 NFE alleles), with 0 homozygotes."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:6182d81c-d3d3-4f5e-b098-0701c67004c0_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:6182d81c-d3d3-4f5e-b098-0701c67004c0","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":26,"allele":{"id":"cggv:a10a828c-fb7e-47b7-a91f-c4d785df3a42","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002633.3(PGM1):c.1145-222G>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2579984136"}},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Proband's CK level was 10000 U/L, lowest blood glucose was 1.8 mM, height was 3pc","phenotypes":["obo:HP_0003236","obo:HP_0003201","obo:HP_0000175","obo:HP_0004322","obo:HP_0001712","obo:HP_0031964","obo:HP_0000193","obo:HP_0001644","obo:HP_0003546","obo:HP_0031956"],"previousTesting":true,"previousTestingDescription":"PGM1 activity was 2.2% of WT.","sex":"Male","variant":{"id":"cggv:cdd31e8e-9648-45c6-bf9c-a1e624243c8a_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:a10a828c-fb7e-47b7-a91f-c4d785df3a42"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24499211"},"rdfs:label":"Tegtmeyer_Proband 5.1"},{"id":"cggv:cdd31e8e-9648-45c6-bf9c-a1e624243c8a","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:cdd31e8e-9648-45c6-bf9c-a1e624243c8a_variant_evidence_item"},{"id":"cggv:cdd31e8e-9648-45c6-bf9c-a1e624243c8a_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"cDNA analysis in siblings showed that the variant uses a cryptic splice donor and results in the inclusion of an exon derived from intronic sequence, causing a frameshift, Gly382ValfsTer23. The resulting premature termination codon occurs in exon 8 out of 11, and NMD is predicted."}],"strengthScore":1.5,"dc:description":"The deep intronic variant is shown to result in early truncation of the mRNA transcript with NMD predicted and hence scored like a loss of function variant. "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:5d32426c-d845-4574-ba86-a928aa0edc41_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:5d32426c-d845-4574-ba86-a928aa0edc41","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":35,"allele":[{"id":"cggv:ace995fc-9d2b-4131-99ac-30ecb9c6052e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002633.3(PGM1):c.343A>G (p.Thr115Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA123324"}},{"id":"cggv:afae50a8-e228-4b20-841f-96e0480e65ca","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002633.3(PGM1):c.1145-1G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA123325"}}],"detectionMethod":"Authors indicate \"molecular testing\", but do not outline the exact methods of detection.","firstTestingMethod":"PCR","phenotypeFreeText":"Proband's CK level was 300 U/L, which increased 10x â€“ 20x after strenuous exercise. Exercise also caused 4x ammonia release. Muscle biopsy showed abnormal subsarcolemmal and sarcoplasmic accumulations of normally structured, free glycogen. in-vitro muscle study of anaerobic glycogenolysis and glycolysis revealed metabolic block after glucose-1-phosphate and before glucose-6-phosphate.\n","phenotypes":["obo:HP_0003749","obo:HP_0003458","obo:HP_0003201"],"previousTesting":true,"previousTestingDescription":"Biochemical investigation of muscle showed reduction of phosphoglucomutase activity to 1% of control\n","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"cggv:0011263e-a71b-443a-88e4-75fe26337c06_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:ace995fc-9d2b-4131-99ac-30ecb9c6052e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19625727"},{"id":"cggv:0acca9a0-9bef-4b3e-8ae9-eb208d256836_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:afae50a8-e228-4b20-841f-96e0480e65ca"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19625727"}],"rdfs:label":"Stojkovic_Proband"},{"id":"cggv:0011263e-a71b-443a-88e4-75fe26337c06","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:0011263e-a71b-443a-88e4-75fe26337c06_variant_evidence_item"},{"id":"cggv:0011263e-a71b-443a-88e4-75fe26337c06_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Lee et al, 2014; PMID: 25288802 assessed the enzyme activity of PGM1 variants in E. coli and showed that the Thr115Ala variant results in about 50% activity of the WT. \n"}],"strengthScore":0.5,"dc:description":"This variant is reported in gnomAD v2.1.1 at a frequency of 0.00001792 (2/111596 non-Finnish European alleles). With functional evidence, the score is increased to 0.5 pts."},{"id":"cggv:0acca9a0-9bef-4b3e-8ae9-eb208d256836","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:0acca9a0-9bef-4b3e-8ae9-eb208d256836_variant_evidence_item"}],"strengthScore":1.5,"dc:description":"The canonical splice acceptor variant occurs in intron 7 and results in skipping of exon 8 and frameshift, with NMD predicted."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:22d404ef-7ca8-4d9b-be0f-ca9a5734ab4f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:22d404ef-7ca8-4d9b-be0f-ca9a5734ab4f","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":16,"allele":{"id":"cggv:0b326bfe-0aa6-4714-8a34-8488345d4c12","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002633.3(PGM1):c.1507C>T (p.Arg503Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA130546"}},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Proband had DCM with severe fractional shortening 5%. Their CK level was 10000 U/L, lowest blood glucose was 1.8 mM, height was <3pc","phenotypes":["obo:HP_0000175","obo:HP_0000193","obo:HP_0031956","obo:HP_0002047","obo:HP_0000201","obo:HP_0006568","obo:HP_0004322","obo:HP_0031964","obo:HP_0001397","obo:HP_0003201","obo:HP_0001644","obo:HP_0003236"],"previousTesting":true,"previousTestingDescription":"PGM1 activity was 7.7% of WT.","sex":"Female","variant":{"id":"cggv:82ec7619-67e5-4ad5-be3d-ed475b6157a0_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:0b326bfe-0aa6-4714-8a34-8488345d4c12"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24499211"},"rdfs:label":"Tegtmeyer_Proband 6"},{"id":"cggv:82ec7619-67e5-4ad5-be3d-ed475b6157a0","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:82ec7619-67e5-4ad5-be3d-ed475b6157a0_variant_evidence_item"}],"strengthScore":1.5,"dc:description":"The Arg503Ter results in early termination in exon 10 out of 11, with NMD predicted. The variant is reported at a frequency of 0.00006533 (2/30616 South Asian alleles) with 0 homozygotes in gnomAD v2.1.1.\n\n"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:1ae8da5f-7a0b-45f5-b60e-20af39cc41c1_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":12},{"id":"cggv:2e903030-dc7c-4a72-974f-f5fc899b1b80_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:2e903030-dc7c-4a72-974f-f5fc899b1b80","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":19,"allele":[{"id":"cggv:7c54f856-8ba9-44bd-b9ec-33d2b331eeea","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002633.3(PGM1):c.988G>C (p.Gly330Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA889678"}},{"id":"cggv:05a8b8b4-178d-40fe-a867-efa267660626","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002633.3(PGM1):c.1129G>A (p.Glu377Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340637291"}}],"detectionMethod":"Variants were detected by Sanger sequencing","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Proband's CK level was 50000 U/L, lowest blood glucose 1 mM, height <5pc","phenotypes":["obo:HP_0003546","obo:HP_0000201","obo:HP_0000193","obo:HP_0031964","obo:HP_0000175","obo:HP_0001397","obo:HP_0003201","obo:HP_0002047","obo:HP_0031956","obo:HP_0001644","obo:HP_0004322","obo:HP_0006568"],"previousTesting":true,"previousTestingDescription":"PGM1 activity was 1.3% of WT","sex":"Female","variant":[{"id":"cggv:9ba98eda-b039-46f5-a9a2-3a031fde5ad7_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:7c54f856-8ba9-44bd-b9ec-33d2b331eeea"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24499211"},{"id":"cggv:5aa5fdae-aceb-46b2-8875-dedc0aa8b8da_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:05a8b8b4-178d-40fe-a867-efa267660626"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24499211"}],"rdfs:label":"Tegtmeyer_Proband 2"},{"id":"cggv:9ba98eda-b039-46f5-a9a2-3a031fde5ad7","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:9ba98eda-b039-46f5-a9a2-3a031fde5ad7_variant_evidence_item"},{"id":"cggv:9ba98eda-b039-46f5-a9a2-3a031fde5ad7_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Lee et al, 2014; PMID: 25288802 showed that when variant was expressed in E. coli cells the resulting PGm1 protein was largely insoluble, with significantly reduced soluble protein."}],"strengthScore":0.5,"dc:description":"The proband was compound heterozygous for two missense variants supported by functional evidence. This Gly330Arg variant is reported at a frequency of 0.0001763 (20/113472 NFE alleles), with 0 homozygotes."},{"id":"cggv:5aa5fdae-aceb-46b2-8875-dedc0aa8b8da","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:5aa5fdae-aceb-46b2-8875-dedc0aa8b8da_variant_evidence_item"},{"id":"cggv:5aa5fdae-aceb-46b2-8875-dedc0aa8b8da_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Lee et al, 2014; PMID: 25288802 showed that when variant was expressed in E. coli cells the resulting PGm1 protein was largely insoluble, with significantly reduced soluble protein."}],"strengthScore":0.5,"dc:description":"The proband was compound heterozygous for two missense variants supported by functional evidence. This Glu377Lys variant is absent in gnomAD."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:3a4e86b3-8bcc-4a31-98ec-97d4ae171d72_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:3a4e86b3-8bcc-4a31-98ec-97d4ae171d72","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":12,"allele":{"id":"cggv:fc9ac29c-b6eb-4ee8-8fd9-d82bb3aae966","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002633.3(PGM1):c.1547T>C (p.Leu516Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA156390"}},"detectionMethod":"Homozygosity mapping and WES was performed in the family","firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"Proband's CK level was 789 U/L and height was <3pc. Lowest blood glucose was 2.6mM","phenotypes":["obo:HP_0003236","obo:HP_0001397","obo:HP_0031956","obo:HP_0031964","obo:HP_0000193","obo:HP_0004322","obo:HP_0000175","obo:HP_0003546","obo:HP_0001395"],"previousTesting":true,"previousTestingDescription":"PGM1 activity was 4.4% of controls. PGM1 protein from fibroblasts assayed by WB was minimal to absent.\n","secondTestingMethod":"Exome sequencing","sex":"Male","variant":{"id":"cggv:c6ccfa97-a1e6-450a-aad7-fa499531a388_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:fc9ac29c-b6eb-4ee8-8fd9-d82bb3aae966"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24499211"},"rdfs:label":"Tegtmeyer_Sib 1.1"},{"id":"cggv:c6ccfa97-a1e6-450a-aad7-fa499531a388","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:c6ccfa97-a1e6-450a-aad7-fa499531a388_variant_evidence_item"},{"id":"cggv:c6ccfa97-a1e6-450a-aad7-fa499531a388_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Lee et al, 2014; PMID: 25288802 showed that when variant was expressed in E. coli cells the resulting PGm1 protein was largely insoluble, with significantly reduced soluble protein.\n"}],"strengthScore":0.5,"dc:description":"The proband and his similarly affected brother were homozygous for the missense variant, Leu516Pro, supported by functional evidence. "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:83ff30c1-2097-4d7d-a72e-aa1b27f81461_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:83ff30c1-2097-4d7d-a72e-aa1b27f81461","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":19,"allele":[{"id":"cggv:f03b8e03-ff94-424d-bfb7-91485f50b522","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002633.3(PGM1):c.1495C>T (p.Arg499Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA889870"}},{"id":"cggv:d5617b6d-9dbd-4c74-992d-9cd761f554ad","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002633.3(PGM1):c.122A>G (p.Gln41Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340639155"}}],"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Proband was resuscitated after cardiac arrest. CK level was <300 U/L. Lowest blood glucose was 1.8 mM. Height was 50pc","phenotypes":["obo:HP_0001396","obo:HP_0031956","obo:HP_0001695","obo:HP_0001395","obo:HP_0031964","obo:HP_0000193","obo:HP_0001397"],"previousTesting":true,"previousTestingDescription":"PGM1 activity was 2.5% of WT","sex":"Male","variant":[{"id":"cggv:b9bf27ba-b78c-47f7-aa94-038fa82c128b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d5617b6d-9dbd-4c74-992d-9cd761f554ad"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24499211"},{"id":"cggv:524bf745-7de7-47bf-82d2-8685d4a77219_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:f03b8e03-ff94-424d-bfb7-91485f50b522"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24499211"}],"rdfs:label":"Tegtmeyer_Proband 4"},{"id":"cggv:b9bf27ba-b78c-47f7-aa94-038fa82c128b","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:b9bf27ba-b78c-47f7-aa94-038fa82c128b_variant_evidence_item"},{"id":"cggv:b9bf27ba-b78c-47f7-aa94-038fa82c128b_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Lee et al, 2014; PMID: 25288802 showed that when variant was expressed in E. coli cells the resulting PGM1 protein was largely insoluble, with significantly reduced soluble protein."}],"strengthScore":0.5,"dc:description":"The Gln41Arg missesnse variant is shown to be functionally abnormal and is reported at a frequency of 0.00002940 (2/68036 NFE alleles) in gnomAD v3.1.1.2."},{"id":"cggv:524bf745-7de7-47bf-82d2-8685d4a77219","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:524bf745-7de7-47bf-82d2-8685d4a77219_variant_evidence_item"}],"strengthScore":1.5,"dc:description":"The Arg499Ter variant results in a nonsense codon in exon 10 out of 11 total exons in the PGM1 gene, with NMD predicted. The variant is reported at a frequency of 0.00002412 (1/41462 African/Afr Am alleles) in gnomAD v3.1.2. "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:a76caaff-bd01-48b1-81a1-f2b4305caa5c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:a76caaff-bd01-48b1-81a1-f2b4305caa5c","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":30,"allele":[{"id":"cggv:c5c11a79-e112-4e3d-8013-e47dc958dd5b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002633.3(PGM1):c.661del (p.Arg221ValfsTer13)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA156394"}},{"id":"cggv:c5bac8eb-c4f0-40e9-a08f-25099e0d4dae"}],"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Proband's CK level was <300 U/L, lowest blood glucose was 3.6 mM, height was <3pc","phenotypes":["obo:HP_0004322","obo:HP_0031956","obo:HP_0000193","obo:HP_0003201","obo:HP_0000175","obo:HP_0003236","obo:HP_0003546","obo:HP_0031964"],"previousTesting":true,"previousTestingDescription":"PGM1 activity was 0.3% of WT","sex":"Female","variant":[{"id":"cggv:9ac5b453-4915-4a34-9226-0d2ccd821053_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c5bac8eb-c4f0-40e9-a08f-25099e0d4dae"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24499211"},{"id":"cggv:90f7c1ad-35db-43e7-8837-b21f87404ea5_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c5c11a79-e112-4e3d-8013-e47dc958dd5b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24499211"}],"rdfs:label":"Tegtmeyer_Proband 16"},{"id":"cggv:9ac5b453-4915-4a34-9226-0d2ccd821053","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:9ac5b453-4915-4a34-9226-0d2ccd821053_variant_evidence_item"},{"id":"cggv:9ac5b453-4915-4a34-9226-0d2ccd821053_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Lee et al, 2014; PMID: 25288802 showed in E. coli cells, that Arg263Tyr variant result in WT levels of expression of soluble protein, but Kcat was 1.1% of WT. "}],"strengthScore":0.5,"dc:description":"The missense variant is supported by functional data and is reported at a frequency of 0.00007349 (5/68032 NFE alleles) with 0 homozygotes in gnomAD v2.1.1."},{"id":"cggv:90f7c1ad-35db-43e7-8837-b21f87404ea5","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:90f7c1ad-35db-43e7-8837-b21f87404ea5_variant_evidence_item"}],"strengthScore":1.5,"dc:description":"The 1-bo deletion, c.661del, results in a frameshift and premature termination, Arg221ValfsTer13, in exon 5 out of 11 and NMD is predicted."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":8309,"specifiedBy":"GeneValidityCriteria10","strengthScore":18,"subject":{"id":"cggv:cc5ad589-f5cf-473d-a80b-cd877fdd519a","type":"GeneValidityProposition","disease":"obo:MONDO_0013968","gene":"hgnc:8905","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"The relationship between *PGM1* and PGM1-Congenital Disorder of Glycosylation (Congenital disorder of glycosylation, type It included), an autosomal recessive disorder, was evaluated using the ClinGen Clinical Validity Framework as of June, 2023. *PGM1* encodes phosphoglucomutase 1, the predominant PGM isoform in most cell types, contributing to 90% of total PGM activity, except red blood cells, wherein PGM2 is the major isoform, and the brain. Redundancy of PGM1 activity in the brain correlates well with the absence of neurological phenotypes in patients with PGM1 deficiency. The primary role of phosphoglucomutase 1 is to catalyze the interconversion of glucose 1-phosphate and glucose 6-phosphate, and it is involved in several crucial metabolic pathways including glycolysis, glycogenolysis, glycogenesis and N-linked glycosylation (PMID: 24499211, 28794993). The clinical manifestations of PGM1-congenital disorder of glycosylation (PGM1-CDG) include bifid uvula, myopathy, hepatopathy, short stature, hypoglycemia and dilated cardiomyopathy.\n \n*PGM1* was first reported in relation to autosomal recessive PGM1-CDG in 2009 (Stojkovic et al, 2009; PMID: 19625727). More than 30 nonsense, splice site, frameshift, deletion/duplication and missense variants have been reported in humans. Evidence supporting this gene-disease relationship includes case-level data and experimental data.\n \nSummary of Case Level Data (12 points): \nVariants in this gene have been reported in at least 8 probands in 2 publication (PMID: 19625727, 24499211). More evidence is available in the literature, but the maximum score for genetic evidence was reached.\n \nThe mechanism for disease is biallelic loss of function.\n \nSummary of experimental data (6 points): \nThis gene-disease relationship is supported by in vitro functional studies, model organisms and rescue evidence. The function of *PGM1* is well understood and the onset of symptoms is associated with defects in glycosylation, which can be rescued to an extent by supplementing with galactose (PMID: 24499211, 28794993). Constitutive knock-out of *Pgm2*, the mouse ortholog of human *PGM1*, leads to embryonic lethality (PMID: 31077402). Cardiomyocyte-specific conditional knock-out of *Pgm2* in mice recapitulates the human dilated cardiomyopathy phenotype seen in some patients with PGM1-CDG (PMID: 36709920). The defect in cKO mice is rescued when AAV-mediated WT *Pgm2* is introduced into the affected animals (PMID: 36709920).\n \nIn summary, *PGM1* is definitively associated with autosomal recessive PGM1-CDG. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the Congenital Disorders of Glycosylation GCEP on August 2nd, 2023.\n","dc:isVersionOf":{"id":"cggv:1ae8da5f-7a0b-45f5-b60e-20af39cc41c1"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}